REGN * Stock Overview
Regeneron Pharmaceuticals, Inc. discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide.
Snowflake Score | |
---|---|
Valuation | 4/6 |
Future Growth | 2/6 |
Past Performance | 2/6 |
Financial Health | 5/6 |
Dividends | 0/6 |
Regeneron Pharmaceuticals, Inc. Competitors
Price History & Performance
Historical stock prices | |
---|---|
Current Share Price | US$15,326.60 |
52 Week High | US$16,380.00 |
52 Week Low | US$11,300.00 |
Beta | 0.14 |
1 Month Change | -4.31% |
3 Month Change | -5.92% |
1 Year Change | 5.11% |
3 Year Change | 55.21% |
5 Year Change | 136.70% |
Change since IPO | 68.87% |
Recent News & Updates
Recent updates
Shareholder Returns
REGN * | MX Biotechs | MX Market | |
---|---|---|---|
7D | -3.0% | 0% | 0% |
1Y | 5.1% | 0% | 0% |
Return vs Industry: REGN * exceeded the MX Biotechs industry which returned -9% over the past year.
Return vs Market: REGN * exceeded the MX Market which returned 1.4% over the past year.
Price Volatility
REGN * volatility | |
---|---|
REGN * Average Weekly Movement | n/a |
Biotechs Industry Average Movement | 0% |
Market Average Movement | 0% |
10% most volatile stocks in MX Market | 0% |
10% least volatile stocks in MX Market | 0% |
Stable Share Price: REGN * has not had significant price volatility in the past 3 months.
Volatility Over Time: Insufficient data to determine REGN *'s volatility change over the past year.
About the Company
Founded | Employees | CEO | Website |
---|---|---|---|
1988 | 13,450 | Leonard Schleifer | www.regeneron.com |
Regeneron Pharmaceuticals, Inc. discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company’s products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity. It also provides Dupixent injection to treat atopic dermatitis and asthma in adults and pediatrics; Libtayo injection to treat metastatic or locally advanced cutaneous squamous cell carcinoma; Praluent injection for heterozygous familial hypercholesterolemia or clinical atherosclerotic cardiovascular disease in adults; REGEN-COV for covid-19; and Kevzara solution for treating rheumatoid arthritis in adults.
Regeneron Pharmaceuticals, Inc. Fundamentals Summary
REGN * fundamental statistics | |
---|---|
Market cap | Mex$1.66t |
Earnings (TTM) | Mex$67.75b |
Revenue (TTM) | Mex$224.76b |
24.5x
P/E Ratio7.4x
P/S RatioIs REGN * overvalued?
See Fair Value and valuation analysisEarnings & Revenue
REGN * income statement (TTM) | |
---|---|
Revenue | US$13.12b |
Cost of Revenue | US$6.25b |
Gross Profit | US$6.86b |
Other Expenses | US$2.91b |
Earnings | US$3.95b |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
May 02, 2024
Earnings per share (EPS) | 36.79 |
Gross Margin | 52.32% |
Net Profit Margin | 30.14% |
Debt/Equity Ratio | 7.6% |
How did REGN * perform over the long term?
See historical performance and comparison